Altered Structural Brain Networks Related to Adrenergic/Muscarinic Receptor Autoantibodies in Chronic Fatigue Syndrome
© 2020 American Society of Neuroimaging..
BACKGROUND AND PURPOSE: Recent studies suggest that the autoantibodies against adrenergic/muscarinic receptors might be one of the causes and potential markers of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The purpose of this study was to investigate the structural network changes related to autoantibody titers against adrenergic/muscarinic receptors in ME/CFS by performing a single-subject gray matter similarity-based structural network analysis.
METHODS: We prospectively examined 89 consecutive right-handed ME/CFS patients who underwent both brain MRI including 3D T1-wighted images and a blood analysis of autoantibodies titers against β1 adrenergic receptor (β1 AdR-Ab), β2 AdR-Ab, M3 acetylcholine receptor (M3 AchR-Ab), and M4 AchR-Ab. Single-subject gray matter similarity-based structural networks were extracted from segmented gray matter images for each patient. We calculated local network properties (betweenness centrality, clustering coefficient, and characteristic path length) and global network properties (normalized path length λ, normalized clustering coefficient γ, and small-world network value δ). We investigated the correlations between the autoantibody titers and regional gray matter/white matter volumes, the local network properties, and the global network properties.
RESULTS: Betweenness centrality showed a significant positive correlation with β1-AdR-Ab in the right dorsolateral prefrontal cortex. The characteristic path length showed a significant negative correlation with β2-AdR-Ab in the right precentral gyrus. There were no significant correlations between the antibody titers and the regional gray matter/white matter volumes, and the global network properties.
CONCLUSIONS: Our findings suggest that β1 AdR-Ab and β2 AdR-Ab are potential markers of ME/CFS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Journal of neuroimaging : official journal of the American Society of Neuroimaging - 30(2020), 6 vom: 18. Nov., Seite 822-827 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fujii, Hiroyuki [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.06.2021 Date Revised 03.06.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jon.12751 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311872972 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311872972 | ||
| 003 | DE-627 | ||
| 005 | 20231225143205.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jon.12751 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1039.xml |
| 035 | |a (DE-627)NLM311872972 | ||
| 035 | |a (NLM)32609410 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fujii, Hiroyuki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Altered Structural Brain Networks Related to Adrenergic/Muscarinic Receptor Autoantibodies in Chronic Fatigue Syndrome |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.06.2021 | ||
| 500 | |a Date Revised 03.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 American Society of Neuroimaging. | ||
| 520 | |a BACKGROUND AND PURPOSE: Recent studies suggest that the autoantibodies against adrenergic/muscarinic receptors might be one of the causes and potential markers of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The purpose of this study was to investigate the structural network changes related to autoantibody titers against adrenergic/muscarinic receptors in ME/CFS by performing a single-subject gray matter similarity-based structural network analysis | ||
| 520 | |a METHODS: We prospectively examined 89 consecutive right-handed ME/CFS patients who underwent both brain MRI including 3D T1-wighted images and a blood analysis of autoantibodies titers against β1 adrenergic receptor (β1 AdR-Ab), β2 AdR-Ab, M3 acetylcholine receptor (M3 AchR-Ab), and M4 AchR-Ab. Single-subject gray matter similarity-based structural networks were extracted from segmented gray matter images for each patient. We calculated local network properties (betweenness centrality, clustering coefficient, and characteristic path length) and global network properties (normalized path length λ, normalized clustering coefficient γ, and small-world network value δ). We investigated the correlations between the autoantibody titers and regional gray matter/white matter volumes, the local network properties, and the global network properties | ||
| 520 | |a RESULTS: Betweenness centrality showed a significant positive correlation with β1-AdR-Ab in the right dorsolateral prefrontal cortex. The characteristic path length showed a significant negative correlation with β2-AdR-Ab in the right precentral gyrus. There were no significant correlations between the antibody titers and the regional gray matter/white matter volumes, and the global network properties | ||
| 520 | |a CONCLUSIONS: Our findings suggest that β1 AdR-Ab and β2 AdR-Ab are potential markers of ME/CFS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a adrenergic/muscarinic receptors | |
| 650 | 4 | |a autoantibodies against | |
| 650 | 4 | |a myalgic encephalomyelitis/chronic fatigue syndrome | |
| 650 | 4 | |a structural network analysis | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Receptors, Adrenergic |2 NLM | |
| 650 | 7 | |a Receptors, Muscarinic |2 NLM | |
| 700 | 1 | |a Sato, Wakiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kimura, Yukio |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuda, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Ota, Miho |e verfasserin |4 aut | |
| 700 | 1 | |a Maikusa, Norihide |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Fumio |e verfasserin |4 aut | |
| 700 | 1 | |a Amano, Keiko |e verfasserin |4 aut | |
| 700 | 1 | |a Shin, Isu |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamura, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Mori, Harushi |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Noriko |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neuroimaging : official journal of the American Society of Neuroimaging |d 1991 |g 30(2020), 6 vom: 18. Nov., Seite 822-827 |w (DE-627)NLM075559684 |x 1552-6569 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2020 |g number:6 |g day:18 |g month:11 |g pages:822-827 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jon.12751 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2020 |e 6 |b 18 |c 11 |h 822-827 | ||